Tesamorelin is a 44-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH), with an added trans-3-hexenoic acid group that increases its stability compared to native GHRH. It acts on the GHRH receptor in the anterior pituitary to stimulate endogenous GH secretion, and has been used in both clinical and pre-clinical research contexts to study GHRH receptor pharmacology.

Research has investigated Tesamorelin's pharmacokinetics in relation to GH pulse stimulation, its receptor binding characteristics, and how GHRH agonism influences downstream IGF-1 signaling in pre-clinical endocrine models. Studies have also examined how its extended stability profile compared to native GHRH affects duration of receptor activation and GH secretion dynamics, making it a useful research tool for characterizing GHRH receptor responses.

Tesamorelin has also been investigated in models examining visceral adipose tissue biology, where GH signaling plays a regulatory role in lipid metabolism pathways — an area that has made it a compound of interest in both endocrinology and metabolic research settings.

myPEPT supplies Tesamorelin at ≥99% verified purity with a Certificate of Analysis from independent third-party lab testing. Lyophilized and shipped across the EU in research-grade packaging.

What researchers should know: Tesamorelin is a research peptide supplied for laboratory use only. While it has a clinical analog, this product is not approved for human use outside of licensed clinical settings. Handle in accordance with your institution's endocrine peptide research protocols and all applicable local regulations.